Finding the Genetic Cause and Therapy for Adhd, Autism and 22q

Discovery of genetic cause and drug therapy for ADHD, autism and 22q that will allow patients to control their symptoms for these three diseases is described. The discovery is by Hakon Hakonarson, MD, Ph.D. who, in 2015, found the genetic cause for the three diseases. He then conducted a clinical trial to prove that the drug NFC-1 could regulate and modulate the genetic mutation that caused the diseases. This is an example of precision medicine being applied to treat the ADHD, autism and 22q patients. The Neighborhood Drug Company (three couples who are neighbors and friends) was instrumental in the success of the company and the development of the therapy for the three diseases.

Discovery of genetic cause and drug therapy for ADHD, autism and 22q that will allow patients to control their symptoms for these three diseases is described. The discovery is by Hakon Hakonarson, MD, Ph.D. who, in 2015, found the genetic cause for the three diseases. He then conducted a clinical trial to prove that the drug NFC-1 could regulate and modulate the genetic mutation that caused the diseases. This is an example of precision medicine being applied to treat the ADHD, autism and 22q patients. The Neighborhood Drug Company (three couples who are neighbors and friends) was instrumental in the success of the company and the development of the therapy for the three diseases.

David H. Moskowitz has practiced law for more than 40 years, taught college for five years and law school for three years, and has been involved in numerous business ventures in real estate construction and development, cosmetics, trucking, manufacturing, etc. for many years. He is the author of Exclusionary Zoning Litigation (1976) and several law-review articles. He graduated from Penn State University (B.S.), Villanova Law School (LL.B), Oxford University (D.Phil.) and spent a post-doctoral year at the National University of Mexico. He lives in Malvern, PA with his wife Marian. He has six children and five grandchildren. He is presently engaged in finishing several real-estate projects and working with Hakon in completing several genetically-based drug therapy projects involving his discoveries.